MEETING ABSTRACT



Open Access

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients

Paula Vieira Freire^{*}, Erika Bezerra Parente, Cristal Peters Cabral, Andre Carvalho Yamaya, Caroline Schnoll, Vivian Roberta Ferreia Simões, Alessandra Muto, Manoel Carlos Sampaio de Almeida Ribeiro, João Eduardo Nunes Salles

From 20th Brazilian Diabetes Society Congress Porto Alegre, Brazil. 11-18 November 2015

Background

It is a common practice to administer basal insulin after oral diabetes agents fail as a first step in insulinization. However, we do not know which regime is better regarding glycemic control: adding basal insulin to sulfonylurea or stopping sulfonylurea and starting a basal bolus regime.

Objective

To compare glycemic variability in T2D patients being treated with two different regimes of diabetes treatment: basal insulin plus sulfonylurea versus basal bolus.

Materials and methods

A retrospective study of a cohort of 51 T2D patients. To evaluate glycemic variability, we collected data from glucometers (accu check 360 software was used to download the data) of all patients that came for physician's appointments at a public hospital between March and June 2015. We analyzed data of mean capillary glucose and its variability (standard deviation) from the 90-day period preceding the final download date. Glycemia and hba1c were also used for this analysis. Chi-square tests and student's t-test were performed for statistical analysis, where p < 0.05 was considered significant.

Results

Of the 417 patients included in this study, 51 were eligible for analysis. 11 patients were using insulin plus sulfonylurea (group 1) and 40 were using basal bolus treatment

* Correspondence: PAULAVF@HOTMAIL.COM

Santa Casa de Misericordia de São Paulo, São Paulo, Brazil

(group 2). The proportion of men and women in each group was 45.5%: 54.5% in group 1 and 32.5%: 67.5% in group 2 (Pearson chi-square p=0.42). There was no difference between treatments regarding A1c and glucose variability (Figure 1).

Conclusion

Sulfonylurea plus basal insulin and basal bolus had the same glucose control and glycemic variability in both patient sample groups.

	Group 1 N (%)	Group 2 N (%)	Total
Women	6 (54.5%)	27 (67.5%)	33 (64.7%)
Men	5 (45.5%)	13 (32.5%)	18 (35.3%)
Total	11 (100%)	40 (100%)	51 (100%)
	Group 1	Group 2	
	Mean \pm SD	Mean \pm SD	p*
	15.0 + 10.7	20.4 ±11.6	0.18
T2DM duration (years)	15.0 ± 10.7	20,4 ±11.0	0.10
T2DM duration (years) BMI (kg /m²)	13.0 ± 10.7 27.0 ± 2.6	$30,5 \pm 6.6$	0.01
T2DM duration (years) BMI (kg /m²) Fasting Glucose (mg/dl)	15.0 ± 10.7 27.0 ± 2.6 153.1 ± 42.3	$30,5 \pm 6.6$ $189,8 \pm 70.5$	0.01
T2DM duration (years) BMI (kg /m²) Fasting Glucose (mg/dl) HbA1c	15.0 ± 10.7 27.0 ± 2.6 153.1 ± 42.3 7.8 ± 0.8	$30,5 \pm 6.6$ $189,8 \pm 70.5$ 8.9 ± 1.7	0.01 0.10 0.05
T2DM duration (years) BMI (kg /m²) Fasting Glucose (mg/dl) HbA1c nº of capillary glucose tests	15.0 ± 10.7 27.0 ± 2.6 153.1 ± 42.3 7.8 ± 0.8 120.0 ± 76.7	$20,4 \pm 11.0$ $30,5 \pm 6.6$ $189,8 \pm 70.5$ 8.9 ± 1.7 132.5 ± 99.3	0.01 0.10 0.05 0.70
T2DM duration (years) BMI (kg /m²) Fasting Glucose (mg/dl) HbA1c nº of capillary glucose tests capillary glucose mean**	13.0 ± 10.7 27.0 ± 2.6 153.1 ± 42.3 7.8 ± 0.8 120.0 ± 76.7 158.8 ± 31.0	$20, \pm 11.0$ $30, 5 \pm 6.6$ $189, 8 \pm 70.5$ 8.9 ± 1.7 132.5 ± 99.3 180.5 ± 49.4	0.01 0.10 0.05 0.70 0.17



© 2015 Freire et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated. Published: 11 November 2015

doi:10.1186/1758-5996-7-S1-A66

Cite this article as: Freire *et al.*: **The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients.** *Diabetology & Metabolic Syndrome* 2015 **7**(Suppl 1):A66.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central